S5 - E5.3 - Strategies to Improve NIT reliability in Diagnosing and Staging MASH Fibrosis
Send us a text This conversation focuses more tightly on the specific challenges with the current approaches that use NITs to diagnose and stage advanced MASH fibrosis and explores several newer options and ways of thinking about the challenge. Roger Green notes that recent papers discuss the failure to predict accurately with FIB-4. He asks how we can improve predictive performance. Louise Campbell notes some specific challenges, after which Jörn Schattenberg praises John Dillon's work in a...
10 Mars 202414min
S5 - E5.2 - NITs In The Diagnosis and Treatment Of Advanced MASH Fibrosis Patients
Send us a text This conversation explores the challenges with using the current non-invasive tests (NITs) to diagnose patients with F2/F3 advanced MASH fibrosis. If tests today cannot achieve the requisite level of precision, panelists explore other ways to define patient targets. Roger Green starts by recalling that in a recent episode (Season 5 Episode 2), Jeff McIntyre suggested that in the US, the initial patient population may be as small as a few hundred thousand people. Ian Rowe stat...
10 Mars 202412min
S5 - E5.1 - Why We Are Focusing On NITs For MASH Diagnosis And Screening
Send us a text This conversation explores why proper use of non-invasive tests (NITs) will play a pivotal role in increasing the number of patients diagnosed and treated for MASH. It becomes particularly pivotal if, as expected, the first MASH drug is approved later this month. Roger Green starts this conversation by describing why he considers NIT use and adoption one of the two pivotal patient treatment issues for 2024. Jörn Schattenberg notes that he has not received any referrals from P...
10 Mars 20248min
S5 - E5 - How Non-Invasive Tests (NITs) For MASLD And MASH Might Evolve In 2024
Send us a text In 2024, the two major areas for change in diagnosing and treating MASH are new drug approval and changes in use of NITs. Naim Alkhouri and Ian Rowe join Jörn Schattenberg, Louise Campbell and Roger Green to consider what might change with NITs and how having an approved drug might change thinking on this issue. 00:00:00 - Surf's Up: Season 5 Episode 5 Opening introduction, including brief quotes taken directly from the episode discussion. 00:02:36 - Introduction and Gr...
7 Mars 202457min
S5 - E4.6 - From The Vault: What a NASH Disease Model Reveals About Treating Advanced Fibrosis
Send us a text Two years ago, Surfing the MASH Tsunami conducted two episodes with Chris Estes, then the chief modeler for the Center for Disease Analysis Foundation exploring issues around CDAF's then-recent publication of a NASH/MASH disease model. This conversation centers on issues of advanced fibrosis. We thought it might be interesting to look back at that episode in lieu of today's topic. Here are the summary notes from 2022: This conversation starts with Chris Estes describing ...
3 Mars 202415min
S5 - E4.5 - MASH Education As A Tool To Stem The MASLD Pandemic
Send us a text As the episode comes to an end, the group winds up focusing on the need for better, more frequent MASH education as a pivotal need if we are to flatten the growth curve of the MASLD pandemic. In the process, the discussion returns to the risk for women and the important role they can play. Louise Campbell starts this conversation by harkening back to the issue of post-menopausal women. As she notes, women provide most of the hands-on care in health system, and also do mo...
3 Mars 20249min
S5 - E 4.4 - Learning about the Global NASH Council's work in MASLD
Send us a text This conversation focuses largely on the work of the Global NASH Council, an effort of over 200 stakeholders in more than 50 countries to address a range of macro issues in the MASLD space. Zobair Younossi, who is the Global NASH Council Chair, starts this conversation by discussing a specific Global NASH Council project on how to implement guidelines for different specialties across regions. He offers two reasons this is such an important project. In general, Zobair notes, 90...
3 Mars 20248min
S5 - E4.1 - Appreciating The Disease Burden Of MASLD
Send us a text In this opening conversation on MASLD disease burden, Zobair Younossi summarizes and expands on some key points from the recent Diabetes Spectrum review article he co-authored with Linda Henry. Zobair starts by discussing the recent review article, Understanding the Burden of Non-Alcoholic Fatty Liver Disease: Time for Action which he describes as "a summary of a large body of evidence that's being generated." He points to three pivotal issues: The treatment burden associated ...
3 Mars 202411min
